2025-05-15-Jefferies-今日RFK参议院和众议院听证会速览及医疗补助削减最新情况_9页_126kb

Summary of Equity Research Report: USA Biotechnology

Key Highlights from RFK Hearings and Policy Updates

• Hearings Overview: RFK Jr. testified before Senate HELP and House Appropriations committees on the HHS budget, addressing vaccines, staff cuts, US manufacturing investments, Maximum Fair Pricing (MFN), and AI in clinical trials. Support for incentives to boost domestic production was noted, but details were limited. Cuts are for consolidation, subject to legal constraints.
• Medicaid Cuts: House proposes $715B in Medicaid cuts, with $912B total budget reduction. This excludes individuals with children caring for dependent children, benefiting Vertex Pharmaceuticals (VRTX) due to its CF treatment market.
• MFN Pricing: Trump's executive order on drug pricing received positive investor reaction. Key points include exclusion of the 180-day negotiation period, potential for higher prices if implemented, criticism of Pharmacy Benefit Managers (PBMs), and warnings from Roark (ROG) about manufacturing commitments. Pharma is likely to gain negotiation time, easing industry concerns.
• Other Policy: Tariffs may soften with US manufacturing investments, potentially avoiding double taxation for new domestic plants.

Company-Specific Valuations and Ratings

• Eli Lilly & Co (LLY): Buy rating, price target of $1,057 based on DCF and sector multiples. Risks: Commercial execution, regulatory delays.
• Roche (ROG): Hold rating, price target CHF270, valuing based on P/E blend and NPV. Risks: Competition, biosimilars.
• Vertex Pharmaceuticals (VRTX): Buy rating, price target $575 per share using SOTP method. Risks: Clinical trial outcomes and competition.

Market Sentiment and Implications

• Investor focus on US policy risks, with MFN and manufacturing incentives potentially mitigating negative impacts on drug stocks. Medicaid exclusions support VRTX, while uncertainty around MFN may yield volatile results for the sector. Analyst conflicts of interest are acknowledged in disclosures.